Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDAThe U.S.Gene Therapy PlatformRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) FDA The U.S. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsNext: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Related Stories Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026 Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026 Regulatory FDA delays verdict on Beren’s rare disease drug by three months pharminent May 29, 2026
